title: Reversal of flecainide-induced ventricular arrhythmia by hypertonic sodium bicarbonate in dogs.
abstract: Flecainide occasionally produces incessant ventricular tachycardia that is difficult to treat. Reports of uncontrolled clinical studies have suggested a therapeutic role for hypertonic sodium bicarbonate (NaHCO3). To test this observation, spontaneous and pacing-induced arrhythmia canine models were designed. In the spontaneous model, flecainide was infused at 0.5 mg/kg/min until ventricular tachycardia occurred spontaneously. In the pacing-induced model, flecainide was infused at 1.0 mg/kg/min load (0.5 mg/kg/min maintenance) stepwise until the QRS was widened 50%, 75%, and 100%, with programmed ventricular stimulation at each step until ventricular arrhythmia was induced. Dogs who developed spontaneous arrhythmia were treated blindly with three doses of either NaHCO3 (3 mEq/kg/dose, with 1 minute between doses) or normal saline. Dogs who were induced in the second model were treated with the same three doses, 10 minutes apart, with programmed stimulation between each dose. Before unblinding in both protocols, dogs were classified as "responders" or "nonresponders" to therapy. In the spontaneous model, of 14 dogs with spontaneous ventricular tachycardia, all 7 dogs treated with NaHCO3 showed response, compared with only 1 of 7 dogs treated with saline (P < .01). Ventricular QRS complexes/min were reduced by NaHCO3 in that protocol. In the induced arrhythmia protocol, of 14 dogs with inducible arrhythmia, 6 of 7 responded to NaHCO3, and 1 of 7 responded to placebo (P < .05). In both protocols, arterial pH and the serum sodium concentration were increased by NaHCO3 but not by normal saline control treatment. QRS interval duration was shortened by NaHCO3 therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Division of Cardiology, Hennepin County Medical Center, University of Minnesota, Minneapolis, USA.
authors.forename: D M
authors.initials: DM
authors.lastname: Salerno
authors.forename: M M
authors.initials: MM
authors.lastname: Murakami
authors.forename: R B
authors.initials: RB
authors.lastname: Johnston
authors.forename: D E
authors.initials: DE
authors.lastname: Keyler
authors.forename: P R
authors.initials: PR
authors.lastname: Pentel
mesh_terms: D000818:Animals; D002304:Cardiac Pacing, Artificial; D004195:Disease Models, Animal; D004285:Dogs; D004562:Electrocardiography; D005424:Flecainide / Q000009:adverse effects*; D006982:Hypertonic Solutions; D017693:Sodium Bicarbonate / Q000627:therapeutic use*; D012965:Sodium Chloride / Q000627:therapeutic use; D017180:Tachycardia, Ventricular / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy
chemical_list: D006982:Hypertonic Solutions; D012965:Sodium Chloride; D017693:Sodium Bicarbonate; D005424:Flecainide